Dihexa

Overview

Dihexa is a nootropic peptide derived from angiotensin IV and marketed on a single eye-catching statistic: in cell culture it is reportedly 10 million times more potent than BDNF at forming new synaptic connections. That figure, which comes from the published research, is exactly why it keeps surfacing in nootropic discussions, and also why it should give people pause.

Our Verdict

The potency that makes dihexa fascinating is also what makes it alarming. There are zero published human clinical trials, zero established safe doses, and zero human pharmacokinetic data. Community reports of cognitive enhancement are largely positive, but the complete absence of basic human safety data places this among the highest-risk compounds we have looked at.

Evidence Quality

Human trials: none. Animal evidence is moderate, showing cognitive improvement in models of impairment. Community reports are sparse, drawn from a small group that describes both cognitive gains and some unsettling side effects. The core uncertainty is blunt: dihexa's human safety profile is genuinely unknown, and being 10 million times more potent at synaptogenesis means the risk of uncontrolled growth effects has never been characterized.

What the Research Shows

Studies indicate dihexa's procognitive action runs through the Hepatocyte Growth Factor/c-Met system. It shows strong antidementia and synaptogenic activity in evaluations, and in APP/PS1 Alzheimer's mouse models it restored cognitive function and memory via the PI3K/AKT pathway. It also protected lateral-line hair cells from aminoglycoside toxicity. For Alzheimer's researchers, the mechanism is worth tracking. For healthy people considering self-dosing for cognition, the risk-reward math is unfavorable given zero human safety data. It is also worth noting the evidence base carries flags: one study retracted and one criticized.

Who Should Be Cautious

Everyone. There are no established safe doses, no human pharmacokinetic data, and no long-term safety record. The very potency that makes dihexa scientifically interesting is what makes unsupervised use risky.

What We Can't Tell You

Whether dihexa is safe for humans at any dose is, quite literally, unknown. This is not the usual "more research needed" line; the basic safety studies have simply never been done.

What the Community Says

Across 189 reports, sentiment was 52% positive, 30% neutral, and 17% negative. Reported benefits included synaptogenesis, motivation, curiosity, creativity, memory, and faster reaction time. The reported side effects are telling: the single most cited was cancer risk, alongside descriptions of feeling "risky," robotic, or humorless, fitting the theoretical growth-pathway concerns.

Dosage

The typical range is 5-20 mg daily, often sublingual. Given its potency, users are advised to start at the lowest effective dose and to cycle in order to gauge effects and safety.

Effectiveness

It is active at very low doses, with effects ranging from dramatic to subtle depending on the individual. Its power calls for careful consideration before use.

Availability

Dihexa is sold as a research chemical by select peptide suppliers, is less widely available than many peptides, and quality is critical, so only reputable sources should be considered.

Bottom Line

The headline potency is real on paper, but the safety vacuum is the whole story here: no human trials, no safe dose, and community chatter about cancer risk. This is one of the riskiest compounds to self-experiment with.